


Annual Report 2021

Impact of COVID-19: regional and cancer alliance results



National Prostate Cancer Audit

NPCA Annual Report 2021. Impact of COVID-19: regional and cancer alliance results

London: The Royal College of Surgeons of England, 2022.



Royal College
of Surgeons
of England

Registered Charity No: 212808

The Royal College of Surgeons of England (RCS) is an independent professional body committed to enabling surgeons to achieve and maintain the highest standards of surgical practice and patient care. As part of this it supports Audit and the evaluation of clinical effectiveness for surgery.

The NPCA is based at the The Clinical Effectiveness Unit (CEU). The CEU is an academic collaboration between The Royal College of Surgeons of England and the London School of Hygiene and Tropical Medicine, and undertakes national clinical audits and research. Since its inception in 1998, the CEU has become a national centre of expertise in methods, organisation, and logistics of large-scale studies of the quality of surgical care. The CEU managed the publication of the NPCA Annual Report, 2020.

In partnership with:



THE BRITISH ASSOCIATION
OF UROLOGICAL SURGEONS

The British Association of Urological Surgeons (BAUS) was founded in 1945 and exists to promote the highest standards of practice in urology, for the benefit of patients, by fostering education, research and clinical excellence. BAUS is a registered charity and qualified medical practitioners practising in the field of urological surgery are eligible to apply for membership. It is intended that this website will be a resource for urologists, their patients, other members of the healthcare team and the wider public.



The British Uro-oncology Group (BUG) was formed in 2004 to meet the needs of clinical and medical oncologists specialising in the field of urology. As the only dedicated professional association for uro-oncologists, its overriding aim is to provide a networking and support forum for discussion and exchange of research and policy ideas.



NATIONAL DISEASE REGISTRATION SERVICE

National Cancer Registration and Analysis Service (NCRAS), Public Health England collects patient-level data from all NHS acute providers and from a range of national data feeds. Data sources are collated using a single data processing system ('Encore') and the management structure is delivered through eight regional offices across England.

The NCRAS is the data collection partner for the NPCA.

Commissioned by:



Healthcare Quality
Improvement Partnership

The Healthcare Quality Improvement Partnership (HQIP) is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of Nursing, and National Voices. Its aim is to promote quality improvement in patient outcomes, and in particular, to increase the impact that clinical audit, outcome review programmes and registries have on healthcare quality in England and Wales. HQIP holds the contract to commission, manage, and develop the National Clinical Audit and Patient Outcomes Programme (NCAPOP), comprising around 40 projects covering care provided to people with a wide range of medical, surgical and mental health conditions. The programme is funded by NHS England, the Welsh Government and, with some individual projects, other devolved administrations and crown dependencies www.hqip.org.uk/national-programmes

All rights reserved. Applications for the copyright owner's written permission to reproduce significant parts of this publication (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) should be addressed to the publisher. Brief extracts from this publication may be reproduced without the written permission of the copyright owner, provided that the source is fully acknowledged.

Copyright © 2022 Healthcare Quality Improvement Partnership (HQIP)

Published January 2022 by the National Prostate Cancer Audit

The Royal College of Surgeons of England
35-43 Lincoln's Inn Fields
London
WC2A 3PE

T 020 7869 6601
E npc@rcseng.ac.uk
www.npc.org.uk

Designed @ www.superbirdcreative.co.uk

Contents

Appendix C1: Number of men diagnosed with PCa/quarter by region and % change 2019 vs 2020.	4
Appendix C2: Number of men diagnosed with PCa/quarter by cancer alliance.	5
Appendix C3: Number of men undergoing RP/quarter by region and % change 2019 vs 2020.	6
Appendix C4: Number of men undergoing RP/quarter by cancer alliance.	7
Appendix C5: Number of men starting RT/quarter by region and % change 2019 vs 2020.	8
Appendix C6: Number of men starting RT/quarter by cancer alliance.	9
Appendix C7: Number of men starting conventional radiotherapy/quarter by region and % change 2019 vs 2020.	10
Appendix C8: Number of men starting hypofractionated radiotherapy/quarter by region and % change 2019 vs 2020.	10
Appendix C9: Number of men with hormone sensitive prostate cancer starting docetaxel/quarter by region.	11
Appendix C10: Number of men with hormone sensitive prostate cancer starting enzalutamide/quarter by region.	11

Appendix C1: Number of men diagnosed with PCa/quarter by region and % change 2019 vs 2020.

Region	2019				2020				% change			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	11045	10559	10177	10805	11783	4844	7375	9041	106.7	45.9	72.5	83.7
East of England	1314	1323	1227	1348	1519	613	916	1118	115.6	46.3	74.7	82.9
London	1326	1396	1258	1445	1567	489	831	1128	118.2	35.0	66.1	78.1
Midlands	2018	1919	1794	1807	2016	817	1300	1582	99.9	42.6	72.5	87.5
North East & Yorkshire	1768	1732	1679	1775	1760	763	1273	1562	99.5	44.1	75.8	88.0
North West	1277	1251	1221	1281	1398	606	854	1102	109.5	48.4	69.9	86.0
South East	2188	1927	1975	2145	2410	961	1487	1824	110.1	49.9	75.3	85.0
South West	1154	1011	1023	1004	1113	595	714	725	96.4	58.9	69.8	72.2

Appendix C2: Number of men diagnosed with PCa/quarter by cancer alliance.

Cancer alliance	2019				2020			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
Cheshire and Merseyside	463	478	428	442	492	206	256	427
East Midlands	724	668	671	654	633	376	429	567
East of England - North	721	691	632	675	847	332	544	550
East of England - South	593	632	595	673	672	281	372	568
Greater Manchester	477	494	478	548	594	234	405	439
Humber, Coast and Vale	307	261	252	283	292	143	201	262
Kent and Medway	409	316	383	397	492	176	262	305
Lancashire and South Cumbria	337	279	315	291	312	166	193	236
North Central London	256	250	213	247	307	82	120	233
North East London	252	222	220	241	303	110	117	193
Northern	559	585	552	629	566	240	410	538
Peninsula	479	439	449	437	509	281	305	199
RM Partners	557	647	555	619	612	213	420	540
Somerset, Wiltshire, Avon & Gloucestershire	675	572	574	567	604	314	409	526
South East London	261	277	270	338	345	84	174	162
South Yorkshire and Bassetlaw	379	379	335	348	393	136	251	296
Surrey and Sussex	683	587	541	664	772	284	450	591
Thames Valley	533	478	511	545	625	237	398	465
Wessex	563	546	540	539	521	264	377	463
West Midlands	1294	1251	1123	1153	1383	441	871	1015
West Yorkshire and Harrogate	523	507	540	515	509	244	411	466

Appendix C3: Number of men undergoing RP/quarter by region and % change 2019 vs 2020.

Region	2019				2020				% change			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	1902	1734	1682	1725	1804	898	1603	1297	94.8	51.8	95.3	75.2
East of England	168	158	147	140	175	66	211	126	104.2	41.8	143.5	90.0
London	293	305	283	288	296	156	250	247	101.0	51.1	88.3	85.8
Midlands	296	239	244	232	218	80	271	177	73.6	33.5	111.1	76.3
North East & Yorkshire	339	307	279	291	301	110	244	193	88.8	35.8	87.5	66.3
North West	167	167	188	187	186	79	180	133	111.4	47.3	95.7	71.1
South East	429	340	342	377	437	243	277	295	101.9	71.5	81.0	78.2
South West	210	218	199	210	191	164	170	126	91.0	75.2	85.4	60.0

Appendix C4: Number of men undergoing RP/quarter by cancer alliance.

Cancer alliance	2019				2020			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
Cheshire and Merseyside	51	44	58	52	54	8	69	42
East Midlands	63	74	87	77	69	17	76	33
East of England - North	88	86	79	71	74	40	101	60
East of England - South	80	72	68	69	101	26	110	66
Greater Manchester	72	68	87	86	75	47	65	53
Humber, Coast and Vale	63	55	59	54	54	28	38	28
Kent and Medway	86	61	58	68	86	29	55	58
Lancashire and South Cumbria	44	55	43	49	57	24	46	38
North Central London	133	140	116	106	127	65	105	93
Northern	84	104	77	85	83	41	80	65
Peninsula	83	72	75	59	69	64	63	31
RM Partners	105	106	107	109	106	66	87	102
Somerset, Wiltshire, Avon & Gloucestershire	127	146	124	151	122	100	107	95
South East London	55	59	60	73	63	25	58	52
South Yorkshire and Bassetlaw	69	66	60	55	68	2	46	34
Surrey and Sussex	127	83	94	100	117	85	72	91
Thames Valley	92	92	87	99	120	47	72	73
Wessex	124	104	103	110	114	82	78	73
West Midlands	233	165	157	155	149	63	195	144
West Yorkshire and Harrogate	123	82	83	97	96	39	80	66

Appendix C5: Number of men starting RT/quarter by region and % change 2019 vs 2020.

Region	2019				2020				% change			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	3524	3048	3162	2934	3131	1658	3879	2393	88.8	54.4	122.7	81.6
East of England	467	422	396	445	379	246	518	302	81.2	58.3	130.8	67.9
London	362	314	309	319	360	135	416	276	99.4	43.0	134.6	86.5
Midlands	717	552	585	541	596	313	659	452	83.1	56.7	112.6	83.5
North East & Yorkshire	547	526	540	520	522	302	654	380	95.4	57.4	121.1	73.1
North West	412	364	453	380	431	230	523	291	104.6	63.2	115.5	76.6
South East	671	565	577	460	571	250	768	492	85.1	44.2	133.1	107.0
South West	348	305	302	269	272	182	341	200	78.2	59.7	112.9	74.3

Appendix C6: Number of men starting RT/quarter by cancer alliance.

Region	2019				2020			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
Cheshire and Merseyside	100	106	137	116	117	93	140	99
East Midlands	210	158	188	167	209	104	199	193
East of England - North	302	288	279	296	243	142	354	210
East of England - South	165	134	117	149	136	104	164	92
Greater Manchester	180	150	201	178	197	77	254	129
Humber, Coast and Vale	80	94	82	56	81	61	67	40
Kent and Medway	127	107	111	52	100	15	128	100
Lancashire and South Cumbria	132	108	115	86	117	60	129	63
North Central London	80	71	59	61	85	32	101	71
North East London	83	63	57	62	64	22	57	22
Northern	189	161	184	175	167	85	236	134
Peninsula	137	132	130	108	105	97	134	116
RM Partners	129	125	128	122	133	54	137	115
Somerset, Wiltshire, Avon & Gloucestershire	211	173	172	161	167	85	207	84
South East London	70	55	65	74	78	27	121	68
South Yorkshire and Bassetlaw	103	129	132	117	109	103	148	81
Surrey and Sussex	222	181	193	119	147	31	230	158
Thames Valley	130	114	94	106	126	68	176	129
Wessex	192	163	179	183	198	136	234	105
West Midlands	507	394	397	374	387	209	460	259
West Yorkshire and Harrogate	175	142	142	172	165	53	203	125

Appendix C7: Number of men starting conventional radiotherapy/quarter by region and % change 2019 vs 2020.

Region	2019				2020				% change			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	842	682	700	578	670	272	562	343	79.6	39.9	80.3	59.3
East of England	70	70	54	55	50	40	66	29	71.4	57.1	122.2	52.7
London	143	109	107	112	131	29	111	69	91.6	26.6	103.7	61.6
Midlands	203	144	163	140	170	68	127	96	83.7	47.2	77.9	68.6
North East & Yorkshire	123	122	115	88	66	53	74	39	53.7	43.4	64.3	44.3
North West	74	71	77	50	68	30	57	30	91.9	42.3	74.0	60.0
South East	158	115	115	80	129	35	100	74	81.6	30.4	87.0	92.5
South West	71	51	69	53	56	17	27	6	78.9	33.3	39.1	11.3

Appendix C8: Number of men starting hypofractionated radiotherapy/quarter by region and % change 2019 vs 2020.

Region	2019				2020				% change			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	2671	2357	2450	2341	2444	1368	3258	1969	91.5	58.0	133.0	84.1
East of England	392	345	336	385	324	200	439	264	82.7	58.0	130.7	68.6
London	215	204	198	201	221	103	298	196	102.8	50.5	150.5	97.5
Midlands	514	407	421	400	424	243	523	347	82.5	59.7	124.2	86.8
North East & Yorkshire	424	404	425	431	454	245	563	304	107.1	60.6	132.5	70.5
North West	337	293	375	329	363	197	463	256	107.7	67.2	123.5	77.8
South East	513	450	462	380	442	215	658	411	86.2	47.8	142.4	108.2
South West	276	254	233	215	216	165	314	191	78.3	65.0	134.8	88.8

Appendix C9: Number of men with hormone sensitive prostate cancer starting docetaxel/quarter by region.

Region	2019				2020			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	548	467	506	485	577	78	129	170
East of England	67	53	76	65	78	15	22	29
London	70	60	59	57	70	1	6	13
Midlands	111	89	85	81	110	25	34	43
North East & Yorkshire	86	77	76	90	84	11	21	39
North West	51	49	61	45	75	5	8	9
South East	117	88	99	94	102	15	25	17
South West	46	51	50	53	58	6	13	20

Appendix C10: Number of men with hormone sensitive prostate cancer starting enzalutamide/quarter by region.

Region	2019				2020			
	Jan - Mar	Apr - June	July - Sept	Oct - Dec	Jan - Mar	Apr - June	July - Sept	Oct - Dec
All	1	1	1	1	0	240	320	451
East of England	1	0	0	0	0	27	25	30
London	0	0	0	0	0	16	27	46
Midlands	0	0	0	0	0	33	39	76
North East & Yorkshire	0	0	0	0	0	39	91	109
North West	0	1	0	1	0	46	45	55
South East	0	0	1	0	0	39	66	84
South West	0	0	0	0	0	40	27	51